Foundations Investment Advisors LLC Has $417,000 Stake in Quest Diagnostics Incorporated $DGX

Foundations Investment Advisors LLC increased its holdings in shares of Quest Diagnostics Incorporated (NYSE:DGX) by 59.6% in the second quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 2,322 shares of the medical research company’s stock after buying an additional 867 shares during the period. Foundations Investment Advisors LLC’s holdings in Quest Diagnostics were worth $417,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors have also recently bought and sold shares of DGX. Y Intercept Hong Kong Ltd bought a new stake in shares of Quest Diagnostics in the 1st quarter valued at about $1,228,000. G&S Capital LLC acquired a new position in Quest Diagnostics during the second quarter valued at approximately $1,262,000. Fred Alger Management LLC increased its stake in Quest Diagnostics by 9.9% in the first quarter. Fred Alger Management LLC now owns 19,378 shares of the medical research company’s stock valued at $3,279,000 after purchasing an additional 1,745 shares in the last quarter. ASR Vermogensbeheer N.V. acquired a new stake in Quest Diagnostics in the first quarter worth $1,408,000. Finally, Martin Capital Partners LLC boosted its position in shares of Quest Diagnostics by 194.2% during the second quarter. Martin Capital Partners LLC now owns 5,107 shares of the medical research company’s stock worth $917,000 after purchasing an additional 3,371 shares in the last quarter. 88.06% of the stock is owned by institutional investors.

Quest Diagnostics Price Performance

NYSE:DGX opened at $186.10 on Thursday. Quest Diagnostics Incorporated has a 52-week low of $148.70 and a 52-week high of $197.55. The company has a market cap of $20.70 billion, a P/E ratio of 21.84, a P/E/G ratio of 2.31 and a beta of 0.58. The company has a debt-to-equity ratio of 0.71, a quick ratio of 1.04 and a current ratio of 1.13. The stock’s 50-day simple moving average is $183.21 and its 200 day simple moving average is $178.40.

Quest Diagnostics (NYSE:DGX) last posted its quarterly earnings results on Tuesday, October 21st. The medical research company reported $2.60 earnings per share for the quarter, beating analysts’ consensus estimates of $2.51 by $0.09. Quest Diagnostics had a return on equity of 15.47% and a net margin of 8.91%.The firm had revenue of $2.82 billion during the quarter, compared to the consensus estimate of $2.73 billion. During the same period last year, the company earned $2.30 earnings per share. The business’s revenue was up 13.2% compared to the same quarter last year. Quest Diagnostics has set its FY 2025 guidance at 9.760-9.840 EPS. As a group, sell-side analysts forecast that Quest Diagnostics Incorporated will post 9.7 EPS for the current fiscal year.

Quest Diagnostics Announces Dividend

The company also recently declared a quarterly dividend, which will be paid on Wednesday, January 28th. Shareholders of record on Tuesday, January 13th will be given a dividend of $0.80 per share. This represents a $3.20 annualized dividend and a yield of 1.7%. The ex-dividend date of this dividend is Tuesday, January 13th. Quest Diagnostics’s dividend payout ratio is 37.56%.

Insiders Place Their Bets

In other news, SVP Michael E. Prevoznik sold 227 shares of Quest Diagnostics stock in a transaction dated Friday, September 26th. The shares were sold at an average price of $188.13, for a total value of $42,705.51. Following the completion of the transaction, the senior vice president owned 38,117 shares of the company’s stock, valued at $7,170,951.21. This trade represents a 0.59% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available at this link. Also, Director Gary M. Pfeiffer sold 1,482 shares of the business’s stock in a transaction dated Wednesday, October 22nd. The stock was sold at an average price of $182.40, for a total transaction of $270,316.80. Following the transaction, the director owned 29,431 shares in the company, valued at $5,368,214.40. This represents a 4.79% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. In the last quarter, insiders sold 30,172 shares of company stock valued at $5,639,001. Corporate insiders own 8.16% of the company’s stock.

Analyst Upgrades and Downgrades

Several analysts recently commented on DGX shares. UBS Group raised their price objective on Quest Diagnostics from $180.00 to $190.00 and gave the stock a “neutral” rating in a research note on Friday, October 17th. Weiss Ratings reiterated a “buy (b)” rating on shares of Quest Diagnostics in a report on Wednesday, October 8th. Baird R W downgraded Quest Diagnostics from a “strong-buy” rating to a “hold” rating in a research note on Monday, August 25th. Piper Sandler boosted their price target on Quest Diagnostics from $190.00 to $200.00 and gave the company a “neutral” rating in a report on Monday, October 27th. Finally, Evercore ISI increased their price objective on Quest Diagnostics from $185.00 to $190.00 and gave the stock an “in-line” rating in a report on Wednesday, October 8th. One investment analyst has rated the stock with a Strong Buy rating, eight have given a Buy rating and ten have given a Hold rating to the company. Based on data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average target price of $196.31.

Quest Diagnostics Profile

Quest Diagnostics Incorporated provides diagnostic testing and services in the United States and internationally. The company develops and delivers diagnostic information services, such as routine, non-routine and advanced clinical testing, anatomic pathology testing, and other diagnostic information services.